APA-viite

Grimm, S. E., Fayter, D., Ramaekers, B. L. T., Petersohn, S., Riemsma, R., Armstrong, N., . . . Joore, M. A. (2019). Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics.

Chicago-tyylinen lähdeviittaus

Grimm, Sabine E., et al. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Pharmacoeconomics 2019.

MLA-viite

Grimm, Sabine E., et al. "Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal." Pharmacoeconomics 2019.

Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.